Enhancing accuracy & throughput

Analytical development insights spanning viral vectors & gene editing

Cell & Gene Therapy Insights 2022; 8(2), 295–302

DOI: 10.18609/cgti.2022.047

Published: 11 March 2022
Santoshkumar Khatwani

David McCall, Commissioning Editor of Cell & Gene Therapy Insight speaks to Santoshkumar Khatwani, Director Analytical Development, Sangamo Therapeutics, Inc.

Dr Santosh Khatwani graduated from the University of Kentucky in 2010 with PhD in Chemistry under the guidance of Prof. Sylvia Daunert. The research work focused on the use of generically engineered recombinant protein and enzymes for bio sensing and biomaterial applications. Furthermore, he obtained postdoctoral training at the University of Minnesota (until 2012) under the supervision of Prof T Andrew Taton and Prof Mark D Distefano with focus on the use of site-specific covalent conjugation for synthesis of protein–DNA conjugates and analytical assays for the generating novel engineered enzymes with improved functional attributes. Dr Khatwani then joined BioVision Inc. in 2012 and served under different capacities until 2017 where he oversaw the manufacture, testing and release of several recombinant protein, enzyme and assays for various metabolically important enzymes. Furthermore, Dr. Khatwani joined the field of cell and gene therapy at multiple companies including Thermofisher Viral Vector Services (formerly Brammer Bio, 2017–2018), Asklepios Biopharmaceuticals (2019) and Sangamo Therapeutics (2018–2019, 2019-present) at various leadership roles where he has led the development of various analytical assays including physicochemical, biophysical and biological assays to support the manufacture and release of viral vectors in cell and gene therapy. Currently Dr. Khatwani is serving as Director of Analytical Development at Sangamo Therapeutics with strong focus on developing analytical solutions and CMC in support of product development at early and late phase of the clinical development.